Bavarian Nordic (OTCPK:BVNR.Y) - Hisse Senedi Fiyatı, Haberler ve Analizler

BVNR.Y Stoklara Genel Bakış

Bavarian Nordic A/S hayat kurtaran aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay

BVNR.Y temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	5/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 62% daha düşük bir oranda işlem görüyor

Kazançlar geçen yıl 54.6% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 3.6% oranında düşmesi öngörülüyor

Bavarian Nordic A/S Rakipler

MannKind

NasdaqGM:MNKD

US$1.9b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

ADMA Biologics

NasdaqGM:ADMA

US$4.5b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bavarian Nordic
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	DKK 8.72
52 Haftanın En Yüksek Seviyesi	DKK 14.60
52 Haftanın En Düşük Seviyesi	DKK 6.86
Beta	1.58
11 Aylık Değişim	-17.23%
3 Aylık Değişim	-31.01%
1 Yıllık Değişim	16.34%
33 Yıllık Değişim	-43.01%
5 Yıllık Değişim	6.73%
Halka arzdan bu yana değişim	47.63%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	BVNR.Y	US Biotechs	US Pazar
7D	-11.0%	-10.3%	-2.1%
1Y	16.3%	13.6%	29.6%

Getiri vs. Endüstri: BVNR.Y geçen yıl % 13.6 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: BVNR.Y geçen yıl % 29.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BVNR.Y's price volatile compared to industry and market?
BVNR.Y volatility
BVNR.Y Average Weekly Movement	6.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: BVNR.Y son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: BVNR.Y 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S hayat kurtaran aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, IMVAMUNE, IMVANEX ve JYNNEOS adları altında çoğalmayan çiçek ve maymun çiçeği aşıları; Rabipur/RabAvert adı altında insan kullanımı için kuduz aşısı; Encepur adı altında kene kaynaklı ensefalit aşısı; ve MVABEA adı altında Ebola aşısı sunmaktadır. Ayrıca çiçek hastalığı tedavisi için MVA-BN; solunum sinsityal virüsü tedavisi için Faz III klinik çalışmalarında olan MVA-BN RSV; SARS-CoV-2 tedavisi için Faz III klinik çalışmasını tamamlayan ABNCoV2 geliştirmektedir.

Bavarian Nordic A/S Temel Bilgiler Özeti

Bavarian Nordic'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BVNR.Y temel i̇stati̇sti̇kler
Piyasa değeri	US$2.05b
Kazançlar(TTM)	US$157.86m
Gelir(TTM)	US$856.60m

13.0x

F/K Oranı

2.4x

P/S Oranı

BVNR.Y aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BVNR.Y gelir tablosu (TTM)
Gelir	DKK 6.07b
Gelir Maliyeti	DKK 2.33b
Brüt Kâr	DKK 3.74b
Diğer Giderler	DKK 2.62b
Kazançlar	DKK 1.12b

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

Mar 05, 2025

Hisse başına kazanç (EPS)	14.24
Brüt Marj	61.57%
Net Kâr Marjı	18.43%
Borç/Özkaynak Oranı	0.1%

BVNR.Y uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BVNR.Y Stoklara Genel Bakış

Ödüller

Risk Analizi

Bavarian Nordic A/S Rakipler

NasdaqGM:MNKD

US$1.9b

NasdaqCM:CPRX

US$2.5b

NasdaqGM:ADMA

US$4.5b

NasdaqGS:AGIO

US$3.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial